Compare SDOT & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDOT | XRTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 2.7M |
| IPO Year | 2019 | 2018 |
| Metric | SDOT | XRTX |
|---|---|---|
| Price | $2.06 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.0K | ★ 51.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 490.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,929,137.00 | N/A |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.08 | N/A |
| 52 Week Low | $0.72 | $0.37 |
| 52 Week High | $13.02 | $1.41 |
| Indicator | SDOT | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 39.95 |
| Support Level | $1.18 | $0.37 |
| Resistance Level | $2.40 | $0.60 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 58.23 | 21.54 |
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.